D-BOARD
Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases
| Coordinatore | UNIVERSITY OF SURREY
Organization address
address: Stag Hill contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.d-board.eu/ |
| Totale costo | 7˙925˙677 € |
| EC contributo | 5˙993˙459 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF SURREY
Organization address
address: Stag Hill contact info |
UK (GUILDFORD) | coordinator | 883˙654.40 |
| 2 |
THE UNIVERSITY OF NOTTINGHAM
Organization address
address: University Park contact info |
UK (NOTTINGHAM) | participant | 778˙426.92 |
| 3 |
UNIVERSITE DE LIEGE
Organization address
city: LIEGE contact info |
BE (LIEGE) | participant | 668˙355.00 |
| 4 |
NORDIC BIOSCIENCE COMPOUND DEVELOPMENT A/S
Organization address
address: Herlev Hovedgade 207 contact info |
DK (Helev) | participant | 648˙277.00 |
| 5 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | participant | 511˙169.60 |
| 6 |
BIOTALENTUM TUDASFEJLESZTO KFT
Organization address
address: AULICH LAJOS UTCA 26 contact info |
HU (GOEDOELLO) | participant | 403˙200.00 |
| 7 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 386˙312.00 |
| 8 |
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO
Organization address
address: Schoemakerstraat 97 contact info |
NL (DEN HAAG) | participant | 363˙643.78 |
| 9 |
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
Organization address
address: SCHLOSSPLATZ 2 contact info |
DE (MUENSTER) | participant | 360˙000.00 |
| 10 |
THE HEBREW UNIVERSITY OF JERUSALEM.
Organization address
address: GIVAT RAM CAMPUS contact info |
IL (JERUSALEM) | participant | 336˙720.00 |
| 11 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 245˙000.00 |
| 12 |
BIOMEDIQ AS
Organization address
address: FRUEBJERGVEJ 3 contact info |
DK (KOBENHAVN) | participant | 187˙470.00 |
| 13 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: Brownlow Hill, Foundation Building 765 contact info |
UK (LIVERPOOL) | participant | 171˙230.39 |
| 14 |
UNIVERSITAETSKLINIKUM AACHEN
Organization address
address: Pauwelsstrasse 30 contact info |
DE (AACHEN) | participant | 50˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Chronic inflammatory diseases of joints are major causes of disability in the ageing population. Osteoarthritis (OA) is one of the most common types of arthritis and a major cause of pain and disability in older individuals. OA is expected to place a heavy burden on European healthcare systems, as European citizens grow older. Cartilage damage in OA is detected radiographically by decreases in joint space width (JSW). However, radiographic evidence is seen only after significant cartilage degradation has already taken place. The early stages of the disease may remain latent and asymptomatic for many years. Therefore, there is an acute need for reliable biomarkers and diagnostic tests that can facilitate earlier diagnosis of OA, and inform the prognosis, monitoring and therapeutic strategies for chronic and disabling forms of this disease. However, there is currently a lack of reliable, quantifiable and easily measured biomarkers that provide an earlier diagnosis of OA, inform on the prognostic of the disease and monitor and predict responses to therapeutic modalities. Biomarkers of tissue turnover in joints can reflect disease relevant biological activity and provide valuable information that may be useful diagnostically and therapeutically, potentially enabling a more rational and personalized approach to healthcare management. The proliferation of omic technologies has facilitated rapid progress in biomarker research. Combinations of omic technologies are dominating the biomarker research arena and are playing increasingly important roles in the identification, validation and qualification of new biomarkers. The aim of the D-BOARD consortium is to bring together leading academic institutions and European Small and Medium Enterprises (SMEs) to focus on the identification, validation and qualification of new combination biomarkers and the development of diagnostic tests capable of subclinical disease diagnosis for degenerative and inflammatory diseases of joints.'
Introduzione (Teaser)
European researchers are working to identify genes and biomarkers that could help diagnose osteoarthritis (OA) at an early stage.